The term ocular pain represents pain in the eye. Ocular Pain can be divided into Chronic Ocular Pain and Acute Ocular Pain based on the Visual Analog Scale for Pain (VAS Pain). The visual analog scale (VAS) is a validated, subjective measure for acute and chronic pain. Scores are recorded by making a handwritten mark on a 10-cm line that represents a continuum between “no pain” and “worst pain.”
The various causes for Acute Ocular Pain include but are not limited to ocular trauma, recurrent corneal erosions, dry eyes, microbial keratitis, glaucoma, episcleritis, scleritis, uveitis, retinal diseases, optic neuropathies, etc. The diagnosis of Acute Ocular Pain is easy but determining the underlying cause is time-consuming and difficult. The initial approach can include determining the clinical history of the patient, and examination of the surface of the eye.
Get FREE sample copy at: https://www.delveinsight.com/sample-request/acute-ocular-pain-market
The Acute Ocular Pain Market Research Report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted Acute Ocular Pain market Size from 2017 to 2030 segmented by seven major markets.
The report provides a detailed current Acute Ocular Pain treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Acute Ocular Pain Market Key Facts
-
As per the study by Dana et al. (2019), the annual incidence rates of dry eye disease in the overall population ranged between 0.55% and 0.87%, with an increasing trend over time. The incidence of dry eye disease was consistently higher among females (2008-2012: 0.81-1.21%) than males.
-
It is observed that Dry eye disease and ocular neuropathic pain (underlying causes of Acute Ocular Pain) are more common among females as compared to males.
Key Benefits of Acute Ocular Pain Market Report
-
Acute Ocular Pain market report provides an in-depth analysis of Acute Ocular Pain Market Size, Share, Trend, and Epidemiology Forecast till 2030 in the seven major markets (i.e. the United States, EU5 (Germany, Italy, Spain, France, and the UK) and Japan.
-
The report will help in developing business strategies by understanding the Acute Ocular Pain Market Trends, recent developments, key players, and future market competition that will shape and drive the market growth in the upcoming years.
-
The market report covers Acute Ocular Pain’s current treatment practices, emerging drugs, market share of the individual therapies in the seven major markets.
-
The report provides a detailed assessment of the Acute Ocular Pain market in terms of market drivers & barriers, unmet needs, market opportunities, patient population, detailed comparative analysis of pipeline products including clinical and non-clinical stage products, and other factors.
The Acute Ocular Pain market size is expected to increase during the forecast period owing to the increase in the incidence of Acute Ocular Pain in the 7MM and the expected launch of emerging therapies.
The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Acute Ocular Pain market size and share by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.
The report gives a thorough detail of the Acute Ocular Pain market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Acute Ocular Pain Therapeutics Market
Acute Ocular Pain is typically treated with a topical steroid, topical NSAID, systemic NSAID, lubricant ointment, gel or drops, bandage contact lens, or a few doses of oral opiate or topical anesthetic. Pain management and treatment options usually depend on the underlying condition. Topical agents target the anterior structures of the eye with minimal systemic absorption. They are frequently prescribed in addition to oral peripheral-acting agents such as acetaminophen or centrally-acting opioid analgesics such as hydrocodone.
To redress the current issues, only a few companies are currently working toward this indication to meet the needs of the market. Pipeline drugs in clinical development are designed to address the major unmet needs in Acute Ocular Pain treatment. The other factors that shall further expedite the growth of the Acute Ocular Pain market include increasing awareness about available treatments during the forecast period.
Acute Ocular Pain Epidemiology
The epidemiology section covers insights about the historical and current Acute Ocular Pain patient pool and forecasted trends for every seven major countries from 2017 to 2030. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Acute Ocular Pain Epidemiology Segmentation
-
Total Incidence of Acute Ocular Pain
-
Incidence of Acute Ocular Pain by Underlying Causes
-
Treatable Cases of Acute Ocular Pain
Acute Ocular Pain Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Acute Ocular Pain market or expected to get launched in the market during the study period. The analysis covers Acute Ocular Pain market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report also covers the Acute Ocular Pain Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the Acute Ocular Pain market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing, patent details, and other information for Acute Ocular Pain emerging therapies.
The current emerging pipeline of Acute Ocular Pain is weak as most of the pipeline products are not in higher phases of the clinical trial. The current unmet need for safe and effective therapies for long-term use offers a great opportunity for the development of novel therapies.
Acute Ocular Pain Companies:
-
Pharmaleads SA/IACTA
-
SiteOne Therapeutics
And others.
Acute Ocular Pain Therapies Covered in the report include:
-
PL265 (DENKI)
-
NaV1.7 inhibitors
And many more.
Table of Content
1. Key Insights
2. Executive Summary
3. Acute Ocular Pain Competitive Intelligence Analysis
4. Acute Ocular Pain Market Overview at a Glance
5. Acute Ocular Pain Disease Background and Overview
6. Acute Ocular Pain Patient Journey
7. Acute Ocular Pain Epidemiology and Patient Population
8. Acute Ocular Pain Treatment Algorithm, Current Treatment, and Medical Practices
9. Acute Ocular Pain Unmet Needs
10. Key Endpoints of Acute Ocular Pain Treatment
11. Acute Ocular Pain Marketed Products
12. Acute Ocular Pain Emerging Therapies
13. Acute Ocular Pain Seven Major Market Analysis
14. Attribute Analysis
15. Acute Ocular Pain Market Outlook (7 major markets)
16. Acute Ocular Pain Access and Reimbursement Overview
17. KOL Views on the Acute Ocular Pain Market.
18. Acute Ocular Pain Market Drivers
19. Acute Ocular Pain Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.
Get FREE sample copy at: https://www.delveinsight.com/sample-request/acute-ocular-pain-market
Healthcare Blogs
Leading Companies in the Eye Disorders Treatment Market
Eye Disorders are one of the major public health issues worldwide, directly attributes to the socio-economic burden as well as the health-related quality of life of the affected person and their families. However, some of the major global pharmaceutical companies in the Eye Disease segments such as Novartis, Roche, Eyenovia, Allergan, Sun Pharma, and others are diligently involved in the therapeutics development to mitigate the treatment gap. For more details, visit: Eye Disorders Treatment Market
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/